Meeting
2022 ASCO Annual Meeting
Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer.
Authors
Elizabeth Joyce
University of Michigan Health System, Ann Arbor, MI
Elizabeth Joyce , Kelley M. Kidwell , Vered Stearns , Daniel F. Hayes , Anna Maria Storniolo , Norah Lynn Henry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Clinical Trial Registration Number
NCT00228956
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6568)
DOI
10.1200/JCO.2022.40.16_suppl.6568
Abstract #
6568
Poster Bd #
351
Abstract Disclosures
Similar Posters
Poster
2016 Cancer Survivorship Symposium
Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial.
First Author: Kunal C. Kadakia
Poster
2023 ASCO Annual Meeting
Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.
First Author: Kayla Polcari
Poster
2018 ASCO Annual Meeting
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.
First Author: Sara A. Hurvitz
Poster
2018 ASCO Annual Meeting
Adherence to hormonal therapy among commercially insured breast cancer patients.
First Author: Hui Zhao